Christopher Raymond
Stock Analyst at Piper Sandler
(3.38)
# 990
Out of 5,030 analysts
135
Total ratings
51.35%
Success rate
2.44%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $229.57 | +23.71% | 13 | Oct 10, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $8 → $9 | $5.04 | +78.75% | 9 | Aug 6, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $92.74 | -24.52% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $143.05 | -19.61% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.53 | +488.24% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $53.23 | +136.73% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.20 | +25.00% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $417.20 | +27.76% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $578.32 | +75.16% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $32.56 | +329.98% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $80.00 | -10.00% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.91 | +580.63% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.94 | +1,162.63% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $16.00 | +375.15% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.67 | +1,397.01% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $14.60 | +126.10% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $4.72 | +48.46% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $16.36 | +34.47% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.93 | +36.75% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $7.77 | +221.75% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $299.20 | -3.74% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $42.33 | -3.14% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $41.82 | -33.04% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $92.55 | -56.78% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.94 | +1,416.43% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.37 | +3,950.63% | 2 | Mar 13, 2020 |
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $229.57
Upside: +23.71%
Ardelyx
Aug 6, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $5.04
Upside: +78.75%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $92.74
Upside: -24.52%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $143.05
Upside: -19.61%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.53
Upside: +488.24%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.23
Upside: +136.73%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.20
Upside: +25.00%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $417.20
Upside: +27.76%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $578.32
Upside: +75.16%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $32.56
Upside: +329.98%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $80.00
Upside: -10.00%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.91
Upside: +580.63%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.94
Upside: +1,162.63%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $16.00
Upside: +375.15%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.67
Upside: +1,397.01%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $14.60
Upside: +126.10%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $4.72
Upside: +48.46%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $16.36
Upside: +34.47%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.93
Upside: +36.75%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $7.77
Upside: +221.75%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $299.20
Upside: -3.74%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $42.33
Upside: -3.14%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $41.82
Upside: -33.04%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $92.55
Upside: -56.78%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.94
Upside: +1,416.43%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.37
Upside: +3,950.63%